SciClone (NAS: SCLN) , a U.S.-based pharmaceutical company that sells licensed drugs on the Chinese market, was down 21% for November after poor quarterly results. In this video, Motley Fool health care analyst David Williamson discusses how a price reduction imposed by the Chinese government on its lead drug, Zadaxin, affected sales. Though the company was able to mitigate the damage, the company's integration of its acquisition of NovaMed isn't going as hoped, which is another factor hurting the company at the moment. Given its strong cash flow, is the sell-off a buying opportunity, or is there additional uncertainty on the horizon?
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why SciClone Lost in November originally appeared on Fool.com.
David Williamson owns shares of Pfizer. Follow him on Twitter @MotleyDavid. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.